What is Opus Genetics's pre-tax stock-based compensation cost?

Opus Genetics (IRD) reported pre-tax stock-based compensation cost of $1.46M in Q1 2026.

How has Opus Genetics's pre-tax stock-based compensation cost changed year-over-year?

Opus Genetics's pre-tax stock-based compensation cost increased by 60.4% year-over-year, from $913K to $1.46M.

What is the long-term trend for Opus Genetics's pre-tax stock-based compensation cost?

Over 4 years (2021 to 2025), Opus Genetics's pre-tax stock-based compensation cost has grown at a 15.4% compound annual growth rate (CAGR), from $1.91M to $3.4M.

Opus Genetics IRD Pre-tax stock-based compensation cost

Pre-tax stock-based compensation cost at other companies

Sarepta Therapeutics, Inc.SRPT

——

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's pre-tax stock-based compensation cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's pre-tax stock-based compensation cost?: Opus Genetics (IRD) reported pre-tax stock-based compensation cost of $1.46M in Q1 2026.
How has Opus Genetics's pre-tax stock-based compensation cost changed year-over-year?: Opus Genetics's pre-tax stock-based compensation cost increased by 60.4% year-over-year, from $913K to $1.46M.
What is the long-term trend for Opus Genetics's pre-tax stock-based compensation cost?: Over 4 years (2021 to 2025), Opus Genetics's pre-tax stock-based compensation cost has grown at a 15.4% compound annual growth rate (CAGR), from $1.91M to $3.4M.